4Q 2017 Results and preliminary annual report

Moss, 27 February 2018

Gentian Diagnostics AS announces its results for the 4th quarter and 2017 preliminary annual results. The highlights include:

11% growth in sales revenue compared to 4Q16, 14 % y/y despite loss of our largest distributor
Increase in sales of fCAL turbo continues
Favorable development for Cystatin C in China

Please find the report enclosed.

The report will also be made available on www.gentian.com.

For further information, please contact:

Bård Sundrehagen CEO, Gentian Diagnostics
E-mail: bard.sundrehagen@gentian.no
Cell Phone: +47 924 14 117

Njaal Kind CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525

MeldingsID: 445248

Moss, 12 February 2026 The Board of Directors of Gentian Diagnostics ASA proposes a dividend of NOK 0.60 per..

Gentian Diagnostics ASA announces an update on the development of its NT proBNP assay. Recent investigations..

Moss, 11 February 2026 Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic..